Roche's (RHHBY.US) innovative therapy has been approved by the FDA for the treatment of acute ischemic stroke in adults.
Tuesday, Mar 4, 2025 8:10 am ET
1min read Genentech, a subsidiary of Roche (RHHBY.US), announced that the U.S. FDA has approved TNKase (tenecteplase) for the treatment of acute ischemic stroke (AIS) in adults. TNKase is a tissue plasminogen activator that dissolves blood clots, administered via a five-second intravenous push. This is faster and more convenient than Activase (also developed by Roche), which requires a 60-minute intravenous infusion after a five-second intravenous push. TNKase is the first stroke drug approved by the FDA in nearly 30 years. The most common side effects are bleeding and allergic reactions. Studies have shown that TNKase is as safe and effective as Activase in patients with acute ischemic stroke.
Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.